Výsledky vyhledávání - "Jacob K.R. Jamison"

Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma

Autor: Rachael A Safyan, Gulam Abbas Manji, Shing Mirn Lee, Rebecca Silva, Susan Elaine Bates, Ruth Aroon White, Jacob K.R. Jamison, Adam Joel Bass, Gary K. Schwartz, Paul Eliezer Oberstein, Tamas Gonda

Publikováno v: Journal of Clinical Oncology. 40:4158-4158

4158 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death with a 5-year survival rate of 10%. Novel strategies for advanced PDAC are a critical need. A DNA hypomethylating agent (HMA) increased tumor-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86b18428e375e866ab0ee8529d8aaa4f
https://doi.org/10.1200/jco.2022.40.16_suppl.4158

Zobrazit plný text záznamu

Improved survival in patients with lung only recurrence after surgical resection of pancreatic ductal adenocarcinoma

Autor: Michael S. May, Alissa Michel, Tristan Lee, Winston Wong, Jacob K.R. Jamison, David Manrique, Samuel M Pan, Jianhua Hu, Rachael A Safyan, Alexander Raufi, Michael Kluger, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji

Publikováno v: Journal of Clinical Oncology. 40:608-608

608 Background: Recurrence rates after resection of pancreatic ductal adenocarcinoma (PDA) can be up to 80%. Prior data suggests that initial site of recurrence influences prognosis. This study aims to compare survival of patients (pts) with resected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69429b22f4a12889d7492e1e00e8d891
https://doi.org/10.1200/jco.2022.40.4_suppl.608

Zobrazit plný text záznamu

Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A single institution experience

Autor: Winston Wong, Jacob K.R. Jamison, Michael S. May, Alissa Michel, Tristan Lee, David Manrique, Alexander Raufi, Samuel M Pan, Rachael A Safyan, David Paul Horowitz, Beth Schrope, Michael Kluger, Lisa A. Kachnic, Jianhua Hu, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji

Publikováno v: Journal of Clinical Oncology. 40:565-565

565 Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a minority of patients (pts) eligible for curative resection. Currently, systemic treatment options for down-staging pts with borderline resectable or locally advance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f2eaa13c9b78614803b572799bd5a38
https://doi.org/10.1200/jco.2022.40.4_suppl.565

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání